Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 258 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Actos Clear all
Completed Not applicable Interventional Results available

Effect of Adipokines in Hemodialysis Patients

NCT01301027
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Denver, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Oct 21, 2026, 1:28 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

NCT01931566
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Pioglitazone, Pioglitazone placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years to 83 Years
Enrollment
3,494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
34
States / cities
Phoenix, Arizona • Sun City, Arizona • Long Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 21, 2026, 1:28 AM EDT
Completed Not applicable Interventional Results available

Exercise and Pioglitazone for HIV-Metabolic Syndromes

NCT00639457
View directory record Official record
Conditions
HIV Infections, Type 2 Diabetes, Obesity, HIV, AIDS, Cardiovascular Disease, Lipodystrophy
Interventions
Pioglitazone, Exercise training
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 21, 2026, 1:28 AM EDT
Completed Phase 4 Interventional

Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba

NCT00926614
View directory record Official record
Conditions
Hepatitis c
Interventions
pioglitazone (Actos), atorvastatin (Lipitor)
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 21, 2026, 1:28 AM EDT
Terminated Phase 3 Interventional

GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus

NCT00226330
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Tesaglitazar, Pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
110
States / cities
Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Oct 21, 2026, 1:28 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

NCT02969798
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
Interventions
Dapagliflozin, Saxagliptin, Pioglitazone, Metformin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 1:28 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

NCT00203996
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions
continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp
Device · Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 21, 2026, 1:28 AM EDT
Terminated Phase 2 Interventional Results available

Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer

NCT01342770
View directory record Official record
Conditions
Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
Interventions
Laboratory Biomarker Analysis, Pioglitazone Hydrochloride, Quality-of-Life Assessment
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 21, 2026, 1:28 AM EDT
Terminated Phase 2 Interventional Results available

Insulin Resistance in Pulmonary Arterial Hypertension

NCT00825266
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
bosentan, Pioglitazone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 21, 2026, 1:28 AM EDT
Completed Phase 4 Interventional Results available

Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes

NCT01432405
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide, Pioglitazone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Oct 21, 2026, 1:28 AM EDT
Recruiting Phase 1 Interventional

SGLT2i, Pioglitazone, and Ketone Production in T2D

NCT07053319
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Empagliflozin 25 MG, Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo, Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
30 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 21, 2026, 1:28 AM EDT
Completed Phase 2 Interventional

Study In People With Type 2 Diabetes

NCT00196989
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone, GW677954
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
69
States / cities
Birmingham, Alabama • Northport, Alabama • Chandler, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 21, 2026, 1:28 AM EDT
Completed Phase 3 Interventional Results available

Add-on to Thiazolidinedione (TZD) Failures

NCT00683878
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo matching Dapagliflozin, Thiazolidinedione (Pioglitazone)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
972 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
57
States / cities
Anniston, Alabama • Ozark, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 21, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients

NCT01103414
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mitoglitazone, Pioglitazone, Placebo
Drug
Lead sponsor
Metabolic Solutions Development Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Chino, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 21, 2026, 1:28 AM EDT
Completed Phase 2 Interventional

Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

NCT00290940
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CS-917, metformin hydrochloride, pioglitazone
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Northport, Alabama • Mesa, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2007 · Synced Oct 21, 2026, 1:28 AM EDT
Withdrawn Phase 2 Interventional

Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma

NCT00604578
View directory record Official record
Conditions
Asthma, Airway Inflammation, Airflow Obstruction, Airway Hyperactivity
Interventions
Pioglitazone Hydrochloride
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 1:28 AM EDT
Recruiting Phase 1Phase 2 Interventional

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

NCT03109288
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cilostazol, Leucovorin, Pirfenidone, Dantrolene, Pioglitazone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 1:28 AM EDT
Completed Early Phase 1 Interventional Results available

Pioglitazone for Idiopathic Gastroparesis

NCT04300127
View directory record Official record
Conditions
Gastroparesis
Interventions
Pioglitazone 30 mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 21, 2026, 1:28 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 21, 2026, 1:28 AM EDT
Completed Phase 4 Interventional Results available

Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia

NCT00231894
View directory record Official record
Conditions
Diabetes, Schizophrenia, Insulin Resistance, Cognitive Impairment
Interventions
Pioglitazone, Life style diet group, Placebo
Drug · Behavioral · Other
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 21, 2026, 1:28 AM EDT
Withdrawn Phase 2 Interventional

Skin Blood Flow Response to Insulin Iontophoresis in Pressure Ulcers of SCI

NCT02585765
View directory record Official record
Conditions
Spinal Cord Injury, Pressure Ulcers
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 21, 2026, 1:28 AM EDT
Withdrawn Phase 2 Interventional

Study the Relationship Between Obesity and Hepatitis C Replication

NCT01157975
View directory record Official record
Conditions
Hepatitis C
Interventions
Pioglitazone, Prednisone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 21, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality

NCT00782795
View directory record Official record
Conditions
Chronic Pancreatitis, Insulin Resistance, Normal or Mildly Abnormal Stool Fat Levels
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 21, 2026, 1:28 AM EDT
Active, not recruiting Phase 2 Interventional

The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia

NCT05919147
View directory record Official record
Conditions
Lung Cancer
Interventions
Pioglitazone 45 mg, Placebo
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 21, 2026, 1:28 AM EDT